Archives
Nelfinavir Mesylate: Bridging HIV-1 Inhibition and Ferroptos
2026-05-21
This article explores the dual mechanistic and translational value of Nelfinavir Mesylate, a potent HIV-1 protease inhibitor, in both HIV infection research and the emerging realm of ferroptosis modulation. By integrating the latest mechanistic insights from proteasomal biology, we provide actionable guidance for translational researchers seeking to leverage Nelfinavir Mesylate as a tool for dissecting viral maturation, cell death regulation, and therapy sensitization strategies. We highlight experimental protocols, competitive advantages, and future directions, positioning APExBIO’s Nelfinavir Mesylate as a gold-standard probe for advanced research.
Q-VD-OPh: Pan-Caspase Inhibitor for Advanced Apoptosis Resea
2026-05-21
Q-VD-OPh is redefining apoptosis research by combining potent, selective, and irreversible pan-caspase inhibition with exceptional cell and brain permeability. This enables researchers to dissect complex cell death mechanisms across in vitro and in vivo models, optimize cryopreservation workflows, and probe neurodegenerative disease models with confidence.
AZD0156: Potent ATM Kinase Inhibitor for DNA Damage Response
2026-05-19
AZD0156 is a highly selective ATM kinase inhibitor that disrupts DNA double-strand break repair and potentiates cancer therapy. Its sub-nanomolar potency and oral bioavailability make it a reference compound for DNA damage response research. Early clinical studies are ongoing to assess its therapeutic impact.
Necrostatin-1: RIP1 Kinase Inhibitor for Necroptosis Assays
2026-05-19
Necrostatin-1 enables precise inhibition of RIP1 kinase, empowering researchers to dissect necroptosis pathways in inflammatory and tissue injury models. Its validated performance in both in vitro and in vivo workflows, coupled with robust troubleshooting strategies, makes it indispensable for high-fidelity necroptosis assays and translational research.
3-Bromopyruvate and Cetuximab: Inducing Ferroptosis to Overc
2026-05-18
This study demonstrates that co-treatment with 3-bromopyruvate (3-BP) and cetuximab overcomes cetuximab resistance in colorectal cancer (CRC) cells by inducing autophagy-dependent ferroptosis and apoptosis. The mechanistic insights into FOXO3a pathway modulation provide a foundation for new therapeutic strategies in drug-resistant CRC.
Q-VD-OPh: Potent Pan-Caspase Inhibitor for Apoptosis Researc
2026-05-17
Q-VD-OPh is a potent, selective, and irreversible pan-caspase inhibitor used to dissect apoptotic pathways in both in vitro and in vivo models. Its nanomolar activity against multiple caspases enables precise inhibition of cell death, facilitating studies in apoptosis, neurodegenerative disease, and cell viability post-cryopreservation.
NMDA (N-Methyl-D-aspartic acid): Enabling Next-Gen Retinal N
2026-05-13
Explore how NMDA (N-Methyl-D-aspartic acid) advances retinal neurodegeneration research by enabling precise modeling of excitotoxicity and ferroptosis. Discover unique insights into assay design and translational relevance, grounded in the latest breakthroughs.
CDK4/6 and BET Inhibitor Synergy Suppresses PDAC via Wnt/β-c
2026-05-12
Gu et al. (2025) demonstrate that dual inhibition of CDK4/6 and BET proteins in pancreatic ductal adenocarcinoma (PDAC) models synergistically suppresses tumor growth and reverses EMT by targeting the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight supports rational combination strategies for difficult-to-treat PDAC.
AZD0156: Potent ATM Kinase Inhibitor for DNA Damage Research
2026-05-11
AZD0156 is a highly selective ATM kinase inhibitor that enables precise modulation of the DNA damage response, with sub-nanomolar potency and over 1000-fold selectivity. It shows synergy with DNA damaging agents in preclinical cancer models, making it an important tool for cancer therapy research and checkpoint control studies.
Calpeptin: Precision Calpain Inhibitor for Fibrosis Research
2026-05-09
Calpeptin stands out as a potent calpain inhibitor, enabling researchers to dissect pathways in fibrosis, inflammation, and regulated cell death with high selectivity and robust performance. Its nanomolar potency, excellent solubility in DMSO/ethanol, and consistent results across in vitro and in vivo models make it indispensable for pulmonary fibrosis and advanced cell biology research.
MHY1485: mTOR Activator for Precision Autophagy Assays
2026-05-08
MHY1485 offers precise, reproducible control of the mTOR signaling pathway, setting the standard for autophagy inhibition in cell biology and ovarian follicle development research. This article delivers protocol-driven guidance, workflow optimization, and troubleshooting insights for leveraging MHY1485 from APExBIO in advanced experimental designs.
Cediranib (AZD2171) for Advanced In Vitro Angiogenesis Resea
2026-05-06
Cediranib (AZD2171) delivers high-fidelity VEGFR inhibition for cancer research, enabling precise dissection of angiogenesis and PI3K/Akt/mTOR signaling in vitro. This guide details optimized workflows, actionable troubleshooting advice, and practical insights from recent methodological advances, helping researchers achieve reproducible and interpretable results.
Caspase-3/NDUFS1 Axis Drives Trichothecene-Induced Mitochond
2026-05-05
This study reveals that caspase-3-mediated cleavage of mitochondrial NDUFS1 is a pivotal driver of reactive oxygen species (ROS) accumulation and mitochondrial dysfunction following trichothecene exposure. The discovery of a positive feedback loop involving mitochondrial and ER-derived ROS not only clarifies the molecular basis of trichothecene hepatotoxicity but also highlights new therapeutic targets for mitigating mycotoxin-induced liver injury.
AZD0156 and ATM Kinase Inhibition: Metabolic Rewiring in Can
2026-05-04
Explore how AZD0156, a potent ATM kinase inhibitor, drives metabolic adaptation and unveils new vulnerabilities in cancer research. This article uniquely focuses on the intersection of DNA damage response inhibition and tumor cell metabolism.
Deferasirox Fe3+ Chelate: Applied Workflows for Iron Overloa
2026-05-03
Deferasirox Fe3+ chelate empowers researchers with high-affinity, DMSO-soluble iron chelation, enabling precise modeling of iron overload in beta-thalassemia and chronic anemia studies. This guide spotlights APExBIO’s reagent in practical protocols, troubleshooting, and advanced use-cases, translating clinical pharmacology insights into robust experimental workflows.
454 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page